An open ended study in which patients who completed the double-blind study (CDP870-050) are given Certolizumab pegol and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00160641?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
